Search research articles
Contact Us
Filters
Showing results (391-400 of 408) with videos related to
Page
of 41
Sort By:
The New England Journal of Medicine
|
January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.
Journal of Viral Hepatitis
|
April 14, 2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
P J Clark, A J Thompson, M Zhu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Michael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Journal of Hepatology
|
August 19, 2007
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
Norbert Bräu, Rena K Fox, Peiying Xiao, et al.
The New England Journal of Medicine
|
July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
John G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine
|
July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Hepatology (Baltimore, Md.)
|
November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis B
Calvin Q Pan, Samer Saadi, Marc G Ghany, et al.
Hepatology (Baltimore, Md.)
|
July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
Mark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
Annals of Hepatology
|
April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Donald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Gastroenterology
|
August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial
Fred Poordad, Eric Lawitz, K Rajender Reddy, et al.
Page
of 41
Search research articles
Search
Showing results (391-400 of 408) with videos related to
Sort By:
Page
of 41
The New England Journal of Medicine
|
January 17, 2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S Sulkowski, David F Gardiner, Maribel Rodriguez-Torres, et al.
Journal of Viral Hepatitis
|
April 14, 2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response
P J Clark, A J Thompson, M Zhu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Michael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Journal of Hepatology
|
August 19, 2007
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
Norbert Bräu, Rena K Fox, Peiying Xiao, et al.
The New England Journal of Medicine
|
July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
John G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine
|
July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Hepatology (Baltimore, Md.)
|
November 4, 2025
Technical systematic review supporting 2025 AASLD practice guidelines on management of chronic hepatitis B
Calvin Q Pan, Samer Saadi, Marc G Ghany, et al.
Hepatology (Baltimore, Md.)
|
July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study
Mark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
Annals of Hepatology
|
April 7, 2016
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
Donald M Jensen, Tarik Asselah, Douglas Dieterich, et al.
Gastroenterology
|
August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial
Fred Poordad, Eric Lawitz, K Rajender Reddy, et al.
Page
of 41